Ingredion authorizes new stock repurchase program for up to 8 million shares

Ingredion Incorporated (NYSE:INGR) announced Monday that its Board of Directors has terminated the company’s existing stock repurchase program and approved a new authorization to repurchase up to 8 million shares of its outstanding common stock. The new program is effective from Tuesday through December 31, 2028.

According to a statement based on a Securities and Exchange Commission filing, approximately 2.1 million shares remained available for repurchase under the previous program at the time of its termination. Under the new authorization, the company may repurchase shares from time to time in the open market, through privately negotiated transactions, or by other means, at prices it considers appropriate.

Ingredion stated that the new repurchase program does not obligate the company to acquire any specific number of shares, and that the program may be suspended, discontinued, or modified at any time and for any reason without notice.

Ingredion’s common stock trades on the New York Stock Exchange under the ticker symbol INGR. The information is based on a press release statement included in the company’s SEC filing.

In other recent news, Ingredion Incorporated announced its financial results for the second quarter of 2025. The company highlighted a strong performance in its healthful solutions segment, although it experienced a slight decline in net sales overall. Despite this, Ingredion maintained its full-year guidance, projecting adjusted earnings per share to be between $11.10 and $11.60. This announcement comes as the company continues to focus on expanding its healthful solutions offerings. Additionally, Ingredion’s stock was recently reviewed by analysts, though specific upgrades or downgrades were not mentioned. Investors are keeping a close eye on these developments as the company progresses through the fiscal year. These recent updates provide insight into Ingredion’s strategic direction and financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.